Filing Flows › Viatris (VTRS) › How it makes money
How Viatris (VTRS) makes money
Viatris (VTRS) made $3.8B of revenue in the third quarter 2026 (Q3 2026), +0.8% from a year earlier. Brands brought in $2.5B (66%); Lipitor brought in $452M (12%); EpiPen® Auto-Injectors brought in $156M (4%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Brands | $2.5B | 65.6% | — | +1% |
| Lipitor | $452M | 12.0% | — | +14% |
| EpiPen® Auto-Injectors | $156M | 4.2% | — | -0.9% |
| Lyrica ® | $114M | 3.0% | — | -10% |
| Creon ® | $98.1M | 2.6% | — | +5% |
| Viagra ® | $94.1M | 2.5% | — | -11% |
| Influvac ® | $90.6M | 2.4% | — | -28% |
| Zoloft ® | $78.8M | 2.1% | — | +18% |
| Yupelri ® | $71.5M | 1.9% | — | +0.1% |
| Celebrex ® | $70.2M | 1.9% | — | -4% |
| Effexor ® | $63.9M | 1.7% | — | -5% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $3.8B | 100.0% |
| Income tax | $453M | 12.1% |
| Operating cash flow | $899M | 24.0% |
| Free cash flow | $814M | 21.7% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $3.7B | -0.3% |
| Q2 2026 | $3.8B | +5% |
| Q1 2026 | $3.5B | +8% |
| Q3 2025 | $3.8B | +0.2% |
| Q2 2025 | $3.6B | -6% |
| Q1 2025 | $3.3B | -11% |
From Viatris' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Viatris make money?
Viatris (VTRS) made $3.8B of revenue in the third quarter 2026 (Q3 2026), +0.8% from a year earlier. Brands brought in $2.5B (66%); Lipitor brought in $452M (12%); EpiPen® Auto-Injectors brought in $156M (4%).
What is Viatris' biggest business?
Brands: $2.5B in the third quarter 2026, 66% of revenue, +1% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.